Structured intelligence on corporate strategy, market moves, and industry signals.
Each entry is a briefing, not a headline: event summary, strategic context, and what to watch next.
A Company Pulse is our reading of what a company says in its own press release, with the questions we would want answered. It is not verified reporting and it is not an endorsement. Pulses are made from press releases we collect from several sources, including Wire. Nobody can pay for a Pulse.
FDA granted Rare Pediatric Disease (RPD) Designation to QRX003 for Peeling Skin Syndrome (PSS), a second RPD designation for the drug after Netherton Syndrome.
Quantum BioPharma (NASDAQ: QNTM) received FDA clearance to begin a phase 2 trial for Lucid-MS, a first-in-class drug candidate targeting demyelination in multiple sclerosis (MS).
SciBase received a $0.6M order from Castle Biosciences for Nevisense Go devices and electrodes to accelerate an ongoing clinical study and prepare for a second study.
